EQS-News

CRMI: Bio-Engineered Cornea 'ACORNEA' Exhibits at 28th Annual Meeting of European Eye Bank Association - Seite 2

materials, such as glass, acrylic and silica gel, often have poor
biocompatibility and mechanical properties. CRMI, therefore, began to
develop "Acornea" since 2003. CRMI applies its tissue engineering technique
on porcine cornea to preserve collagen architecture of the corneal matrix
so that it can quickly integrate with patients' corneal tissue. The
transplanted cornea will gradually become transparent, thus leading to a
recovery of patients' vision. Clinical trial data shows an overall
transplantation efficacy of 94.44%, with recovery rates very similar to
that of donated corneas. Over the years, with tremendous devotion and
dedication from CRMI, the self-developed "Acornea" has completed all the
necessary clinical trials and obtained its product certificate approved by
the China Food and Drug Administration. Moreover, it is the world's first
clinically-approved bio-engineered cornea. "Acornea" is also an important
milestone for CRMI in the area of regenerative medicine and tissue
engineering.

"Acornea" is now available in the market and can greatly ease the shortage
of donated corneas, bringing hope to over 4 million patients with corneal
diseases in China and over 60 million patients worldwide.

-End-

About CRMI
CRMI is listed on the GEM board of The Stock Exchange of Hong Kong Limited
with stock code 8158. The Company is principally engaged in research and
development of bio-medical and healthcare products, and medical techniques;
the provision of the production and sales of tissue engineering products
and its related derivatives; as well as sales and distribution of medical
products and equipment.

About European Eye Bank Association
Founded in 1989 in Italy, EEBA is a technical-scientific organisation
comprising individual members from 84 eye banks from 24 European countries.
It is formed for the advancement of eye banking. Its mission is to help
provide tissues and cells of optimum quality and safety for transplantation
and the treatment of eye diseases, according to the highest medical and
scientific standards; EEBA also contributes to the development and
maintenance of standards for the practice of eye banking in Europe.

Issued by Financial PR (HK) Limited For and on behalf of China Regenerative
Medicine International Limited

For further information, please contact:
Financial PR (HK) Limited
Mr. James Lo [e-mail]
Ms. Cindy Lo [e-mail]
Tel: [phone]
Fax: [phone]




End of Press Release

+++++


Document: http://n.eqs.com/c/fncls.ssp?u=HODNEWNNFJ
Document title: CRMI: Bio-Engineered Cornea 'ACORNEA' Exhibits at 28th
Annual Meeting of European Eye Bank Association

---------------------------------------------------------------------------

Key word(s): Market launch

25/01/2016 Dissemination of a Press Release, transmitted by EQS TodayIR - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

---------------------------------------------------------------------------


431781 25/01/2016